Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A M Eggermont

Showing results (21-30 of 171) with videos related to

Pageof 18
Sort By:
Journal of Inflammation|January 1, 1995
Regional application of TNF alpha in the treatment of cancer: a preclinical-clinical interactive programA M Eggermont, E R Manusama, T L ten Hagen
Nederlands Tijdschrift Voor Geneeskunde|February 6, 1993
[Thyroid metastases as cause of thyroid swelling]M J van der Sangen, T Wiggers, A M Eggermont
Journal of Cancer Research and Clinical Oncology|January 1, 1997
Cyclosporin A enhances locoregional metastasis of the CC531 rat colon tumourW Van de Vrie, R L Marquet, A M Eggermont
Journal of Biological Response Modifiers|August 1, 1987
Inhibitory effects of alloimmune T cells on the generation of cytolytic responses of lymphokine-activated killer cellsP H Sugarbaker, W Matthews, E P Steller, et al.
British Journal of Cancer|August 1, 1987
Alloimmune cells consume interleukin-2 and competitively inhibit the anti-tumour effects of interleukin-2A M Eggermont, E P Steller, W Matthews, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1986
Recruitment of inflammatory cells to a tumor deposit potentiates the immunotherapeutic effects of interleukin-2E P Steller, A M Eggermont, W Matthews, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1987
Synergistic antitumor activity of cyclophosphamide and ABPP in the treatment of established and advanced tumors in murine tumor modelsA M Eggermont, P H Sugarbaker, R L Marquet, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1988
In vivo generation of lymphokine activated killer cell activity by ABPP and interleukin-2 and their antitumor effects against immunogenic and nonimmunogenic tumors in murine tumor modelsA M Eggermont, P H Sugarbaker, R L Marquet, et al.
Cancer|October 1, 1987
The requirements for successful immunotherapy of intraperitoneal cancer using interleukin-2 and lymphokine-activated killer cellsR T Ottow, A M Eggermont, E P Steller, et al.
Agents and Actions|January 1, 1989
Treatment of colon cancer in rats with rMuTNF and the interferon-inducer bropirimineR L Marquet, R W de Bruin, A M Eggermont, et al.
Pageof 18

Showing results (21-30 of 171) with videos related to

Sort By:
Pageof 18
Journal of Inflammation|January 1, 1995
Regional application of TNF alpha in the treatment of cancer: a preclinical-clinical interactive programA M Eggermont, E R Manusama, T L ten Hagen
Nederlands Tijdschrift Voor Geneeskunde|February 6, 1993
[Thyroid metastases as cause of thyroid swelling]M J van der Sangen, T Wiggers, A M Eggermont
Journal of Cancer Research and Clinical Oncology|January 1, 1997
Cyclosporin A enhances locoregional metastasis of the CC531 rat colon tumourW Van de Vrie, R L Marquet, A M Eggermont
Journal of Biological Response Modifiers|August 1, 1987
Inhibitory effects of alloimmune T cells on the generation of cytolytic responses of lymphokine-activated killer cellsP H Sugarbaker, W Matthews, E P Steller, et al.
British Journal of Cancer|August 1, 1987
Alloimmune cells consume interleukin-2 and competitively inhibit the anti-tumour effects of interleukin-2A M Eggermont, E P Steller, W Matthews, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1986
Recruitment of inflammatory cells to a tumor deposit potentiates the immunotherapeutic effects of interleukin-2E P Steller, A M Eggermont, W Matthews, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1987
Synergistic antitumor activity of cyclophosphamide and ABPP in the treatment of established and advanced tumors in murine tumor modelsA M Eggermont, P H Sugarbaker, R L Marquet, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1988
In vivo generation of lymphokine activated killer cell activity by ABPP and interleukin-2 and their antitumor effects against immunogenic and nonimmunogenic tumors in murine tumor modelsA M Eggermont, P H Sugarbaker, R L Marquet, et al.
Cancer|October 1, 1987
The requirements for successful immunotherapy of intraperitoneal cancer using interleukin-2 and lymphokine-activated killer cellsR T Ottow, A M Eggermont, E P Steller, et al.
Agents and Actions|January 1, 1989
Treatment of colon cancer in rats with rMuTNF and the interferon-inducer bropirimineR L Marquet, R W de Bruin, A M Eggermont, et al.
Pageof 18